Standard of Care and Treatment Options

Treating distal renal tubular acidosis (dRTA) is a commitment to balancing your body’s internal chemistry. Because your kidneys cannot remove acid on their own, you must provide the “antacid” the body needs through daily medication. This is known as alkali therapy ^[1][2].

For inherited dRTA, this is a lifelong commitment. For acquired dRTA, treatment may not be lifelong if the underlying cause (such as an autoimmune flare or medication effect) is successfully reversed. The goal of treatment is simple but vital: to stop acid from building up in the blood, which protects the bones, ensures normal growth in children, and reduces the risk of kidney stones ^[1][3].

The Targets for Success

Your medical team will use blood and urine tests to “tune” your dosage. The primary goal is to return your serum bicarbonate levels to an individualized target set by your clinician, often aiming near the normal range of 23 and 28 mEq/L ^[1][4]. Never adjust your dose on your own based on a lab reading; appropriate targets vary by age and kidney function.

In addition to bicarbonate, doctors monitor:

• Potassium levels: dRTA often causes the kidneys to “waste” potassium. Keeping this in the normal range is essential for muscle and heart health ^[5][6].
• Urinary Calcium: If the treatment is working, the amount of calcium in your urine should drop. This is a sign that the medication is protecting your kidneys from stones and calcium deposits (nephrocalcinosis) ^[7][8].

Choosing the Right Medication

There are several types of alkali medication. The choice depends on your specific blood chemistry and how well you tolerate the taste and side effects.

Navigating the “Treatment Burden”

Historically, dRTA has been a difficult disease to manage because standard alkali medications wear off quickly. This often meant taking four, five, or even six doses a day—including waking up in the middle of the night to take a dose ^[9][11].

This “treatment burden” can lead to:

• Gastrointestinal (GI) distress: Bloating, gas, or stomach pain ^[11].
• Poor Adherence: Missing doses, especially at night, allows acid to build back up, which can trigger more kidney stone formation ^[9].

Extended-Release Therapy

A newer medication called ADV7103 (marketed as Sibnayal in some regions) has changed the landscape for many patients. It is a prolonged-release granule containing both potassium citrate and potassium bicarbonate ^[9].

• Twice-Daily Dosing: Unlike traditional treatments, it is designed to last longer in the body, typically requiring only two doses per day (morning and evening) ^[11].
• Improved Adherence: In specific clinical studies, patients switching to this long-acting version were much more likely to keep their bicarbonate levels in the healthy range (90% success rate vs. 43% on standard care) ^[11].
• Better Quality of Life: Patients reported fewer stomach issues and a significant improvement in daily life because they no longer had to wake up for nighttime dosing ^[12][13].

Note: While ADV7103 is approved by the European Medicines Agency (EMA) for use in dRTA, availability varies by country and age group. Because it contains potassium, it carries the same safety risks regarding hyperkalemia and requires regular blood monitoring. Talk to your nephrologist to see if it is approved and appropriate for your situation ^[9].

Long-Term Outlook

With consistent treatment, the outlook for dRTA is excellent. In a large study of dRTA patients, about half achieved “perfect” control of their lab values, and those who did had better growth and stronger kidney function over time ^[7]. Your treatment reduces your risk of kidney and bone complications over your lifetime ^[14].